51 results about "Muramyl dipeptide" patented technology

The invention discloses a compound type biological active peptide product for livestock and poultry, which is formed by mixing the following components in percent by mass: 1%-7% of functional active peptide, 10%-40% of probiotics, 5%-20% of prebiotics, and the balance of auxiliary materials, wherein the functional peptide is one or a combination of several of collagen peptide, glutathione, muramyl dipeptide, soybean protein peptide and casein phosphopeptide. The probiotics refers to one or a combination of several of lactic acid bacteria, saccharomycetes, photosynthetic bacteria, actinomycetes, bacillus and streptococcus faecalis. The prebiotics is one or a combination of several of isomalto-oligosaccharide, fructo-oligosaccharide, galactooligosaccharide and xylo-oligosaccharide. The auxiliary materials refer to one or a combination of several of silkworm chrysalis, fish meal, montmorillonite, diatomite, zeolite powder, corn flour, bran and bean pulp. Additive amount of the product accounts for 0.1%-0.2% of the amount of feed, and the feed can be directly fed after the product is added and uniformly mixed. The compound type biological active peptide product disclosed by the invention belongs to the micro-ecological technical product and is green and environment-friendly.

The invention provides an immunity enhancing agent, an inactivated vaccine, and a preparation method thereof. The invention relates to the field of biopharmaceutical. The immunity enhancing agent comprises 0.1-21mg/mL of monophosphoryl lipid A, 1.5-125mg/mL of muramyl dipeptide, and 0.7-4.5mg/mL of beta-glucan. The invention also provides the inactivated vaccine comprising the immunity enhancing agent, and a preparation method of the inactivated vaccine. According to the invention, the immunity enhancing agent is mixed with an inactivated antigen solution, such that a water-phase solution is obtained; and the water-phase solution is mixed with an oil-phase solution, such that the inactivated vaccine is obtained. According to the immunity enhancing agent provided by the invention, with a synergetic effect of the components, body immunity level can be improved, and immune response to antigen can be improved, such that antibody level after immunization can be increased, immune window period can be shortened, and vaccine immunization effect can be enhanced. According to the inactivated vaccine comprising the immunity enhancing agent, antibody level after immunization is high, a protection period is long, and immunization window period is short.

This invention is directed to novel oxamyl depeptide ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.

The invention provides a PED (Porcine Epedemic Diarrhea) inactivated vaccine and a preparation method thereof and relates to the field of biopharmacy. The PED inactivated vaccine comprises inactivated PEDV (Porcine Epedemic Diarrhea Virus), and is characterized in that the PED inactivated vaccine comprises 0.05-10 mg/mL Beta-glucosylceramide, 0.1-21 mg/mL monophosphoryl lipid A, 1.5-125 mg/mL muramyl dipeptide and 0.7-4.5 mg/mL Beta-glucan. According to the ingredients of the PED inactivated vaccine, Beta-glucosylceramide, monophosphoryl phosphoryl lipid A, muramyl dipeptide and Beta-glucan have the synergistic effect, the immune response of animals to antigens in the vaccine is significantly improved, the immune window phase is shortened, the antibody production duration of the animal body is obviously prolonged, the serum antibody level is improved, and the level of total intestinal mucosa secretory antibodies (the total SIgA) is improved.

The invention relates to a compound immunoenhancement agent and an application thereof on preparing a vaccine for birds. The compound immunoenhancement agent contains 5ng-10mg/mL of poly IC, 10ng-10mg/mL of muramyl dipeptide, 10ng-5mg/mL of levamisole, 10ng-5mg/mL of resiquimod and 10ng-5mg/mL of imiquimod. After the immunoenhancement agent and H5 hypotype bird flu inactivated vaccine are mixed together, antibody can be produced one week earlier, and the antibody titer is improved above 1.8log2. After chicken are immunized through H5 hypotype bird flu inactivated vaccine, H9 hypotype bird flu vaccine or infectious bronchitis vaccine which contains the compound vaccine immunoenhancement agent, the window phases of the antibody production are shortened, the antibody titer of the vaccine is improved, the immunization duration is prolonged, and the probability of infection disease is reduced.

The invention discloses a substituted muramyl dipeptide compound and a preparation method and applications thereof, and further discloses a pharmaceutical composition of the compound and applications of the pharmaceutical composition. The substituted muramyl dipeptide compound can antagonize human derived or mouse derived immune cell NOD1 and/or NOD2 mediated inflammation NF-[kappa]B and MAPKs signal transduction pathway and inhibit the growth and metastasis of tumors.

The invention discloses a lactobacillus casei ghost, a preparation method and an application thereof, belonging to the biotechnology field. According to the lactobacillus casei ghost, lactobacillus casei is used as a research object, a recombinant vector containing cloned lytic genes is converted into the lactobacillus casei through separation of bacteriophage of the lactobacillus casei, and prediction and cloning of the lytic genes, and then the lytic genes are induced to be expressed to prepare the lactobacillus casei ghost. The lactobacillus casei ghost is used as an antigen delivery carrier safely and reliably in the true sense; besides, muramyl dipeptide in the cell wall of the lactobacillus casei has a good adjuvant effect and can remarkably enhance the immunogenicity of heterogeneous antigen; furthermore, the mass production of the lactobacillus casei ghost can be realized through fermentation, and the lactobacillus casei ghost can be preserved at room temperature for a long time after being frozen and dried, so that the cost for application of production practice is further reduced; and a new idea and a new method for further designing a novel, safe and effective drug, particularly a vaccine delivery system, which are applied to the prevention and treatment of the diseases are provided.

The invention provides a freezing protection solution for the articular cartilage. The freezing protection solution is prepared from, by weight, 18-22 parts of carboxymethyl starch, 2-3 parts of rhamnose, 1-2 parts of cetene, 2-4 parts of microcrystalline cellulose, 4-6 parts of galactomannan, 4-6 parts of muramyl dipeptide, 3-5 parts of palmitoyl pentapeptide-3, 0.5-1.5 parts of alpha-arbutin and70 parts of deionized water. The invention further provides a freezing preservation method for the articular cartilage by adopting the freezing protection solution for the articular cartilage. The method comprises the steps of leaching, dripping of the partial freezing protection solution, addition of a remaining freezing protection solution and program cooling. According to the freezing protection solution, a freezing protection agent, harmful to cells, such as dimethyl sulfoxide is not used; according to the freezing preservation method for the articular cartilage, in the eighth week afterthe articular cartilage is frozen for storage, the articular cartilage is taken, and after temperature recovery, the cell survival rate of the articular cartilage is 82-85%, and the cell survival rateof the articular cartilage is 78-80% in the tenth week.

The present invention relates to the field of virology. More specifically, the present invention provides methods and compositions useful for treating human cytomegalovirus using bacterial cell wall components MDP and tri-DAP as vaccine adjuvants. In specific embodiments, the present invention provides a pharmaceutical composition comprising a human cytomegalovirus vaccine and a NOD1 activator and/or a NOD2 activator. In particular embodiments, the NOD2 activator is muramyl dipeptide (MDP) or a derivative thereof. In certain embodiments, the NOD1 activator is L-Ala-γ-D-Glu-meso-diamino-pimelic acid (tri-DAP) or a derivative thereof.

The invention discloses a compound proplis feed additive capable of accelerating pigs to grow and fatten and improving immunity and a preparation method thereof, belonging to the field of animal feed. The feed additive is prepared from the components in parts by weight: 15-45 parts of proplis, 10-30 parts of gynostemma pentaphylla, 15-45 parts of flower of poplar, 15-30 parts of echinacea purpurea, 15-35 parts of isomaltose hypgather and 10-20 parts of muramyl dipeptide. The compound proplis feed additive has the beneficial effects of reasonable formula and is simple to prepare. The compound does not have toxic and side effect, is free from pollution, is free from medicine residue, does not have medicine tolerance, is subjected to ultra-fine pulverization and has high bioavailability. After application, the compound proplis feed additive is proved to have special efficiency on accelerating pigs to grow and fatten and improving immunity.

The invention discloses gordoniasinensis, a preparation method and application. Gordonia sinensis sq-15 with the preservation number of CCTCC (China Center for Type Culture Collection) NO: M2013065 can generate muramyl dipeptide, lipopolysaccharide, carotene, carotenoid, flavone and a plurality of amino acids, in particular gamma-aminobutyric acid, vitamin and a plurality of trace elements in a czapek's medium. The generated components are organically and harmoniously in a system, so that the physiological function of the system can be sufficiently enhanced; the gordoniasinensis can play a synergetic effect when being combined with other inoculums, such as bacillus subtilis, bacillus licheniformis, or selenium enriched saccharomyces cerevisiae, to prepare different medicinal compositions, and can effectively improve the body immunity to achieve the aims of resisting oxidation, regulating intestinal tracts, and regulating heart vessels.

Disclosed are novel compositions and methods for the treatment of Multiple Sclerosis (MS), and in particular immunostimulatory compositions comprising muramyl dipeptide microparticles for use, e.g., in the treatment of MS.

The invention discloses an animal immune adjuvant as well as a preparation method and an application method thereof, relates to a medical preparation characterized in an immunostimulation additive, in particular to an immunostimulation additive for animals, and aims at providing an animal immune adjuvant which is free of a toxic or side effect and is used for directly modifying the antigen-reinforced immune effect, and a preparation method and an application method of the animal immune adjuvant. The animal immune adjuvant comprises an oil agent and an immunoenhancer; the oil agent comprises liquid paraffin and a surfactant; the surfactant comprises lanolin and span-80; and the immunoenhancer comprises a bacillus calmette guerin vaccine, muramyl dipeptide, levomisole and nanoscale hydroxyapatite. The animal immune adjuvant prepared by the method is capable of effectively inducing cellular immunity and humoral immune response of antigenic specificity; and the antibody with high valence and high sensitivity is obtained by kinds of modifications. The animal immune adjuvant is applied to the fields of immunology and in vitro diagnosis.

By taking guide functions of specific cellular immunity and monoclonal antibody immunity generated in vaccine inoculation as theoretical basis, the effective component of bacillus calmette Guerin (BCG), namely muramyl dipeptide (MDP), and a monoclonal antibody Rituximab of lymphoma cell membrane resistant antigen CD20 are combined to prepare a muramyl dipeptide-anti-CD20 immune conjugate, namely MDP-Rituximab, wherein in-vivo and in-vitro anti-tumour effects of immunocompetent cells subjected to BCG immunity under mediation of MDP-Rituximab are known. The conjugate disclosed by the invention keeps the immunogenicity of MDP, stimulates organisms to generate specific T cell immune response, and brings MDP to be around residual lymphoma cells with the help of immune guide function that a Rituximab antibody is combined with lymphoma cell membrane CD20 molecules; the final purpose of eliminating residual tumours is achieved through immune response mediated by MDP induced T cells; therefore, due to the method, the drug resistance caused by exclusive use of Rituximab is overcome; furthermore, the use amount of the antibody is reduced; and the application prospect of the muramyl dipeptide-anti-CD20 immune conjugate in malignant lymphoma is predicted.

The present invention relates to an immunostimulant and to the use of an immunostimulant in the form of a cross-linked muramyl dipeptide microparticle in the treatment of radiation exposure, radiation poisoning, and mitigating the toxic effects of radiotherapy.